Consensus Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Real-time Estimate Cboe BZX Other stock markets 03:10:45 2024-04-25 pm EDT			5-day change	1st Jan Change
2.31 ^USD	-1.70%		-6.54%	+27.26%

Apr. 09	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT
Mar. 21	Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	MT

Evolution of the average Target Price on Taysha Gene Therapies, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f00983cc808454589589b.tFmPoT6c4XhfGvAL6aZortWCnGYx7e-rxTelJxB_JLI.zT3bylL9vihueYlcu9wk5ZroxiFHm9jggk3CSyUce_7HYMfgfNq2MnJ3uQ~6338cec1145465206a6fe0b3096fd11c

Analyst Recommendations on Taysha Gene Therapies, Inc.

Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	Apr. 09	MT
Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	Mar. 21	MT
Needham Adjusts Taysha Gene Therapies Price Target to $7 From $5, Maintains Buy Rating	Mar. 20	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $6, Keeps Overweight Rating	Nov. 15	MT
Truist Securities Adjusts Price Target on Taysha Gene Therapies to $5 From $6, Maintains Buy Rating	23-09-20	MT
Canaccord Genuity Adjusts Price Target on Taysha Gene Therapies to $6 From $7, Maintains Buy Rating	23-09-20	MT
North American Morning Briefing : Fed Seen Holding Rates, Powell Comments Key	23-09-20	DJ
Truist Securities Raises Price Target on Taysha Gene Therapies to $6 From $2, Maintains Buy Rating	23-08-15	MT
Baird Adjusts Price Target on Taysha Gene Therapies to $8 From $6, Maintains Outperform Rating	23-08-15	MT
Needham Adjusts Price Target on Taysha Gene Therapies to $5 From $6, Keeps Buy Rating	23-08-15	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $7 From $2, Maintains Overweight Rating	23-08-14	MT
SMBC Nikko Trims Taysha Gene Therapies' Price Target to $2 From $3, Maintains Outperform Rating	23-03-30	MT
Morgan Stanley Adjusts Taysha Gene Therapies' Price Target to $1 From $3, Keeps Equalweight Rating	23-03-30	MT
Cantor Fitzgerald Adjusts Price Target on Taysha Gene Therapies to $2 From $13, Maintains Overweight Rating	23-03-30	MT
Chardan Trims Price Target on Taysha Gene Therapies to $5 From $6, Keeps Buy Rating	23-03-30	MT
BTIG Downgrades Taysha Gene Therapies to Neutral From Buy	23-02-02	MT
Canaccord Genuity Adjusts Taysha Gene Therapies' Price Target to $13 From $17, Keeps Buy Rating	23-02-01	MT
Chardan Adjusts Taysha Gene Therapies' Price Target to $6 From $16, Keeps Buy Rating	23-02-01	MT
Truist Securities Adjusts Taysha Gene Therapies' Price Target to $4 From $15, Keeps Buy Rating	23-02-01	MT
Needham Adjusts Taysha Gene Therapies' Price Target to $6 From $16, Keeps Buy Rating	23-02-01	MT
Jefferies Downgrades Taysha Gene Therapies to Hold From Buy, Adjusts Price Target to $1.50 From $14	23-02-01	MT
JMP Securities Adjusts Price Target on Taysha Gene Therapies to $4 From $6, Maintains Market Outperform Rating	23-02-01	MT
Baird Adjusts Price Target on Taysha Gene Therapies to $6 From $10, Maintains Outperform Rating	23-02-01	MT
Morgan Stanley Downgrades Taysha Gene Therapies to Equal Weight From Overweight, $3 Price Target	23-01-27	MT
JMP Securities Adjusts Price Target on Taysha Gene Therapies to $6 From $20, Maintains Market Outperform Rating	23-01-19	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.35 USD

Average target price

6.833 USD

Spread / Average Target

+190.78%

High Price Target

9 USD

Spread / Highest target

+282.98%

Low Price Target

5 USD

Spread / Lowest Target

+112.77%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Taysha Gene Therapies, Inc.

Piper Sandler
Chardan Research
Needham & Co.
Cantor Fitzgerald
Truist Securities
Canaccord Genuity
Baird
Morgan Stanley
SMBC Nikko
BTIG
Jefferies & Co.
JMP Securities
Wells Fargo Securities
Goldman Sachs
Wedbush
Oppenheimer
Guggenheim
Chardan

Ratings for Taysha Gene Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar